Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firmonertinib Adjuvant Therapy in Resected Stage IA EGFR-Mutated NSCLC
ChiCTR2600121611Phase 4Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of furmonertinib in EGFR-mutated non-small cell lung cancer, sponsored by Peking Union Medical College Hospital. Primary endpoint: 3-year disease-free survival rate. Started Apr 2026; status: recruiting.
02
Drugs
furmonertinib
03
Conditions
EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on ChiCTR2600121611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121611.